Aim: To develop the purified HFRS bivalent vaccine.
Methods: LR1 (type I) and R22 (type II) of HFRS virus were cultured respectively in Vero cells. The viral suspensions were harvested, inactivated with beta-propiolactone, concentrated by ultra-filtration, purified by zone centrifugation, and desucrosed by column chromatography. The qualified vaccine bulks of type I and type II were mixed equally and absorbed with AI(OH)3 for preparation of 3 lots vaccines.
Results: The 3 lots vaccines all passed examination carried out by ourselves and reexamination performed by National Institute for the Control of Pharmaceutical and Biological Products . One of 3 lots has been used in clinical trial.
Conclusion: It is practical to develop the purified HFRS bivalent vaccine by Vero cell culture.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!